Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term persistence of hepatitis A antibodies after prior Havrix vaccination
2013-001918-15Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Hepatitis A virus vaccine in hepatitis A (HAV), sponsored by GSK. Primary endpoints: Anti-HAV seropositivity status and Anti-HAV geometric mean concentration. Started Apr 2014; status: completed.
02
Drugs
Hepatitis A virus vaccine
03
Conditions
hepatitis A (HAV)
Beyond the preview
Go deeper on 2013-001918-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001918-15.